Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1

Yuan Shih Hu, Jeehaeh Do, Chandrakanth Reddy Edamakanti, Ameet R. Kini, Marco Martina, Samuel I Stupp, Puneet Opal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There is increasing appreciation for the role of the neurovascular unit in neurodegenerative diseases. We showed previously that the angiogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnormally low levels in spinocerebellar ataxia type 1 (SCA1), and that replenishing VEGF reverses the cerebellar pathology in SCA1 mice. In that study, however, we used a recombinant VEGF, which is extremely costly to manufacture and biologically unstable as well as immunogenic. To develop a more viable therapy, here we test a synthetic VEGF peptide amphiphile that self-assembles into nanoparticles. We show that this nano-VEGF has potent neurotrophic and angiogenic properties, is well-tolerated, and leads to functional improvement in SCA1 mice even when administered at advanced stages of the disease. This approach can be generalized to other neurotrophic factors or molecules that act in a paracrine manner, offering a novel therapeutic strategy for neurodegenerative conditions.

Original languageEnglish
Pages (from-to)312-321
Number of pages10
JournalBrain : a journal of neurology
Volume142
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Spinocerebellar Ataxias
Nanoparticles
Vascular Endothelial Growth Factor A
Nerve Growth Factors
Neurodegenerative Diseases
Pathology
Cytokines
Peptides
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1. / Hu, Yuan Shih; Do, Jeehaeh; Edamakanti, Chandrakanth Reddy; Kini, Ameet R.; Martina, Marco; Stupp, Samuel I; Opal, Puneet.

In: Brain : a journal of neurology, Vol. 142, No. 2, 01.02.2019, p. 312-321.

Research output: Contribution to journalArticle

Hu, Yuan Shih ; Do, Jeehaeh ; Edamakanti, Chandrakanth Reddy ; Kini, Ameet R. ; Martina, Marco ; Stupp, Samuel I ; Opal, Puneet. / Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1. In: Brain : a journal of neurology. 2019 ; Vol. 142, No. 2. pp. 312-321.
@article{83a3bc5a45bc4d64b19f7d8febcd138c,
title = "Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1",
abstract = "There is increasing appreciation for the role of the neurovascular unit in neurodegenerative diseases. We showed previously that the angiogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnormally low levels in spinocerebellar ataxia type 1 (SCA1), and that replenishing VEGF reverses the cerebellar pathology in SCA1 mice. In that study, however, we used a recombinant VEGF, which is extremely costly to manufacture and biologically unstable as well as immunogenic. To develop a more viable therapy, here we test a synthetic VEGF peptide amphiphile that self-assembles into nanoparticles. We show that this nano-VEGF has potent neurotrophic and angiogenic properties, is well-tolerated, and leads to functional improvement in SCA1 mice even when administered at advanced stages of the disease. This approach can be generalized to other neurotrophic factors or molecules that act in a paracrine manner, offering a novel therapeutic strategy for neurodegenerative conditions.",
author = "Hu, {Yuan Shih} and Jeehaeh Do and Edamakanti, {Chandrakanth Reddy} and Kini, {Ameet R.} and Marco Martina and Stupp, {Samuel I} and Puneet Opal",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/brain/awy328",
language = "English",
volume = "142",
pages = "312--321",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1

AU - Hu, Yuan Shih

AU - Do, Jeehaeh

AU - Edamakanti, Chandrakanth Reddy

AU - Kini, Ameet R.

AU - Martina, Marco

AU - Stupp, Samuel I

AU - Opal, Puneet

PY - 2019/2/1

Y1 - 2019/2/1

N2 - There is increasing appreciation for the role of the neurovascular unit in neurodegenerative diseases. We showed previously that the angiogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnormally low levels in spinocerebellar ataxia type 1 (SCA1), and that replenishing VEGF reverses the cerebellar pathology in SCA1 mice. In that study, however, we used a recombinant VEGF, which is extremely costly to manufacture and biologically unstable as well as immunogenic. To develop a more viable therapy, here we test a synthetic VEGF peptide amphiphile that self-assembles into nanoparticles. We show that this nano-VEGF has potent neurotrophic and angiogenic properties, is well-tolerated, and leads to functional improvement in SCA1 mice even when administered at advanced stages of the disease. This approach can be generalized to other neurotrophic factors or molecules that act in a paracrine manner, offering a novel therapeutic strategy for neurodegenerative conditions.

AB - There is increasing appreciation for the role of the neurovascular unit in neurodegenerative diseases. We showed previously that the angiogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnormally low levels in spinocerebellar ataxia type 1 (SCA1), and that replenishing VEGF reverses the cerebellar pathology in SCA1 mice. In that study, however, we used a recombinant VEGF, which is extremely costly to manufacture and biologically unstable as well as immunogenic. To develop a more viable therapy, here we test a synthetic VEGF peptide amphiphile that self-assembles into nanoparticles. We show that this nano-VEGF has potent neurotrophic and angiogenic properties, is well-tolerated, and leads to functional improvement in SCA1 mice even when administered at advanced stages of the disease. This approach can be generalized to other neurotrophic factors or molecules that act in a paracrine manner, offering a novel therapeutic strategy for neurodegenerative conditions.

UR - http://www.scopus.com/inward/record.url?scp=85060803730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060803730&partnerID=8YFLogxK

U2 - 10.1093/brain/awy328

DO - 10.1093/brain/awy328

M3 - Article

C2 - 30649233

AN - SCOPUS:85060803730

VL - 142

SP - 312

EP - 321

JO - Brain

JF - Brain

SN - 0006-8950

IS - 2

ER -